{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:12:57Z","timestamp":1785859977129,"version":"3.56.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.micpath.2024.107051","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:46:57Z","timestamp":1729525617000},"page":"107051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Influenza B virus: Target and acting mechanism of antiviral drugs"],"prefix":"10.1016","volume":"197","author":[{"given":"Jicheng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3961\/jpmph.19.156","article-title":"Estimating influenza-associated mortality in Korea: the 2009-2016 seasons","volume":"52","author":"Hong","year":"2019","journal-title":"J. Prevent. Med. Pub. Health = Yebang Uihakhoe chi"},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.cmi.2019.02.011","article-title":"European all-cause excess and influenza-attributable mortality in the 2017\/18 season: should the burden of influenza B be reconsidered?","volume":"25","author":"Nielsen","year":"2019","journal-title":"Clin. Microbiol. Infection : Off. Pub. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10096-020-03822-x","article-title":"Comparison of clinical outcomes of influenza A and B at the 2017-2018 influenza season: a cohort study","volume":"39","author":"Avni","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/v14061323","article-title":"Influenza B: prospects for the development of cross-protective vaccines","volume":"14","author":"Tsybalova","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.micpath.2024.107051_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104970","article-title":"Burden of influenza B virus infection and considerations for clinical management","volume":"185","author":"Zaraket","year":"2021","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.micpath.2024.107051_bib6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4643","article-title":"Hospitalization for influenza A versus B","volume":"138","author":"Tran","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7589\/0090-3558-45.2.519","article-title":"Serologic evidence of influenza A and B viruses in South American fur seals (Arctocephalus australis)","volume":"45","author":"Blanc","year":"2009","journal-title":"J. Wildl. Dis."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.7589\/JWD-D-20-00175","article-title":"Antibodies against influenza virus types a and B in CANADIAN seals","volume":"57","author":"Measures","year":"2021","journal-title":"J. Wildl. Dis."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/irv.12588","article-title":"Influenza B viruses in pigs, Taiwan","volume":"13","author":"Tsai","year":"2019","journal-title":"Influenza Other Respir. Viruses"},{"issue":"5468","key":"10.1016\/j.micpath.2024.107051_bib10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1126\/science.288.5468.1051","article-title":"Influenza B virus in seals","volume":"288","author":"Osterhaus","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1073\/pnas.1916585116","article-title":"Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity","volume":"117","author":"Virk","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.micpath.2024.107051_bib12","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1002\/jmv.26990","article-title":"A brief review of influenza virus infection","volume":"93","author":"Javanian","year":"2021","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib13","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41564-019-0513-7","article-title":"The structure of the influenza A virus genome","volume":"4","author":"Dadonaite","year":"2019","journal-title":"Nat. Microbiol."},{"issue":"18","key":"10.1016\/j.micpath.2024.107051_bib14","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1177\/1535370220953151","article-title":"Hsa-miR-30e-3p inhibits influenza B virus replication by targeting viral NA and NP genes","volume":"245","author":"Khongnomnan","year":"2020","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/jvi.29.1.361-373.1979","article-title":"Influenza B virus genome: assignment of viral polypeptides to RNA segments","volume":"29","author":"Racaniello","year":"1979","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/v11040346","article-title":"Influenza hemagglutinin and neuraminidase: yin\u207bYang proteins coevolving to thwart immunity","volume":"11","author":"Kosik","year":"2019","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14656566.2020.1856814","article-title":"Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors","volume":"22","author":"Zhang","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.tim.2019.03.001","article-title":"Influenza neuraminidase: underrated role in receptor binding","volume":"27","author":"Wen","year":"2019","journal-title":"Trends Microbiol."},{"issue":"21","key":"10.1016\/j.micpath.2024.107051_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200821119","article-title":"Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface","volume":"119","author":"Zhu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11427-009-0060-1","article-title":"Structure-function studies of the influenza virus RNA polymerase PA subunit","volume":"52","author":"Liu","year":"2009","journal-title":"Sci. China C Life Sci."},{"issue":"19","key":"10.1016\/j.micpath.2024.107051_bib21","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1021\/bi036139e","article-title":"Structure-function relationship of the influenza virus RNA polymerase: primer-binding site on the PB1 subunit","volume":"43","author":"Kolpashchikov","year":"2004","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/v13050780","article-title":"Influenza virus RNA synthesis and the innate immune response","volume":"13","author":"Weis","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4149\/av_2013_02_113","article-title":"The RNA polymerase of influenza a virus: mechanisms of viral transcription and replication","volume":"57","author":"Fodor","year":"2013","journal-title":"Acta Virol."},{"issue":"9","key":"10.1016\/j.micpath.2024.107051_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038398","article-title":"Structure and function of the influenza virus transcription and replication machinery","volume":"10","author":"Fodor","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19053018","article-title":"Antiviral drugs in influenza","volume":"19","author":"\u015awierczy\u0144ska","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"13","key":"10.1016\/j.micpath.2024.107051_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1099\/0022-1317-33-1-159","article-title":"Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action","volume":"33","author":"Palese","year":"1976","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0969-2126(93)90005-2","article-title":"Influenza B virus neuraminidase can synthesize its own inhibitor","volume":"1","author":"Burmeister","year":"1993","journal-title":"Structure"},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v11100947","article-title":"The symmetry of viral sialic acid binding sites-implications for antiviral strategies","volume":"11","author":"Rustmeier","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.micpath.2024.107051_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/B978-0-12-405880-4.00006-8","article-title":"Influenza virus resistance to antiviral therapy","volume":"67","author":"van der Vries","year":"2013","journal-title":"Adv. Pharmacol."},{"issue":"3","key":"10.1016\/j.micpath.2024.107051_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx105","article-title":"A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir","volume":"4","author":"Abed","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01081-18","article-title":"Characterization of influenza B virus variants with reduced neuraminidase inhibitor susceptibility","volume":"62","author":"Farrukee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107051_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105280","article-title":"Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors","volume":"200","author":"Brown","year":"2022","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.micpath.2024.107051_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/irv.12713","article-title":"Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons","volume":"14","author":"Kato-Miyashita","year":"2020","journal-title":"Influenza Other Respir. Viruses"},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7883\/yoken.JJID.2020.084","article-title":"Detection of a peramivir-resistant influenza B\/Yamagata-Lineage virus imported from Indonesia in Aichi, Japan, march 2019","volume":"73","author":"Takashita","year":"2020","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107051_bib36","series-title":"Oseltamivir. StatPearls, (StatPearls Publishing Copyright \u00a9 2022","author":"Sur","year":"2022"},{"issue":"8","key":"10.1016\/j.micpath.2024.107051_bib37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.drudis.2020.06.004","article-title":"Oseltamivir analogs with potent anti-influenza virus activity","volume":"25","author":"Kumar","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib38","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1080\/07391102.2020.1765872","article-title":"Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase","volume":"39","author":"Kato","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11020237","article-title":"Inhibition of influenza virus replication by oseltamivir derivatives","volume":"11","author":"Chan","year":"2022","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/003655401750064040","article-title":"Zanamivir: a rational approach to influenza B","volume":"33","author":"Penn","year":"2001","journal-title":"Scand. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib41","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/AAC.01628-10","article-title":"Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system","volume":"55","author":"Brown","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010678","article-title":"Alloferon and zanamivir show effective antiviral activity against influenza A virus (H1N1) infection in vitro and in vivo","volume":"24","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/phar.2330","article-title":"Peramivir for influenza A and B viral infections: a pharmacokinetic case series","volume":"39","author":"Cies","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib44","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1038\/s41598-017-07433-z","article-title":"Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection","volume":"7","author":"Pascua","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107051_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/IDR.S86460","article-title":"Peramivir injection in the treatment of acute influenza: a review of the literature","volume":"9","author":"Wester","year":"2016","journal-title":"Infect. Drug Resist."},{"issue":"8","key":"10.1016\/j.micpath.2024.107051_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3851\/IMP3158","article-title":"Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors","volume":"22","author":"Fage","year":"2017","journal-title":"Antivir. Ther."},{"issue":"32","key":"10.1016\/j.micpath.2024.107051_bib47","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e212","article-title":"Safety and effectiveness of peramivir in Korean adult influenza patients: prospective observational study based on post-marketing surveillance data","volume":"33","author":"Choi","year":"2018","journal-title":"J. Kor. Med. Sci."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/irv.12187","article-title":"Peramivir and laninamivir susceptibility of circulating influenza A and B viruses","volume":"8","author":"Leang","year":"2014","journal-title":"Influenza Other Respir. Viruses"},{"issue":"20","key":"10.1016\/j.micpath.2024.107051_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012244","article-title":"Evolution of influenza viruses-drug resistance, treatment options, and prospects","volume":"23","author":"Smyk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"12","key":"10.1016\/j.micpath.2024.107051_bib51","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jiac.2019.05.008","article-title":"Drug-induced pneumonitis following the administration of laninamivir octanoate: the first two reported cases","volume":"25","author":"Ogawa","year":"2019","journal-title":"J. Infect. Chemother."},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib52","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jiac.2021.06.004","article-title":"The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance","volume":"27","author":"Nakano","year":"2021","journal-title":"J. Infect. Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10156-011-0292-4","article-title":"High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals","volume":"18","author":"Kubo","year":"2012","journal-title":"J. Infect. Chemother."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib55","first-page":"44","article-title":"\u91d1\u82b1\u6e05\u611f\u9897\u7c92\u8054\u5408\u78f7\u9178\u5965\u53f8\u4ed6\u97e6\u5bf9\u7532\u578b\u6d41\u611f\u60a3\u8005\u8840\u6e05\u708e\u75c7\u56e0\u5b50\u6c34\u5e73\u53ca\u514d\u75ab\u529f\u80fd\u7684\u5f71\u54cd %J \u57fa\u5c42\u533b\u5b66\u8bba\u575b","volume":"27","year":"2023"},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002249","article-title":"Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition","volume":"7","author":"Vavricka","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41467-021-27950-w","article-title":"Mapping inhibitory sites on the RNA polymerase of the 1918 pandemic influenza virus using nanobodies","volume":"13","author":"Keown","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/acs.jmedchem.1c01527","article-title":"Lead optimization of influenza virus RNA polymerase inhibitors targeting PA-PB1 interaction","volume":"65","author":"Mizuta","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107051_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101279","article-title":"Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy","volume":"57","author":"Stevaert","year":"2022","journal-title":"Curr. Opin. Virol."},{"issue":"12","key":"10.1016\/j.micpath.2024.107051_bib60","first-page":"751","article-title":"Influenza: diagnosis and treatment","volume":"100","author":"Gaitonde","year":"2019","journal-title":"Am. Fam. Physician"},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2024.107051_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217307","article-title":"Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models","volume":"14","author":"Fukao","year":"2019","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.micpath.2024.107051_bib64","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib65","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038463","article-title":"Influenza therapeutics in clinical practice-challenges and recent advances","volume":"11","author":"Beigel","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib66","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2024.107051_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2175","article-title":"Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: a mini-review","volume":"31","author":"Abed","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.micpath.2024.107051_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105281","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020","volume":"200","author":"Govorkova","year":"2022","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01056-22","article-title":"Effect of baloxavir and oseltamivir in combination on infection with influenza viruses with PA\/I38T or PA\/E23K substitutions in the ferret model","volume":"13","author":"Koszalka","year":"2022","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib70","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jiaa164","article-title":"Treatment-emergent influenza virus polymerase acidic substitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil","volume":"222","author":"Ince","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib71","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.micpath.2024.107051_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10081631","article-title":"Inhibitors of nucleotide biosynthesis as candidates for a wide spectrum of antiviral chemotherapy","volume":"10","author":"Sep\u00falveda","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2024.107051_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2015.04.016","article-title":"Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect","volume":"209","author":"Guo","year":"2015","journal-title":"J. Contr. Release : Off. J. Controll. Rel. Soc."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/tera.1420170117","article-title":"Teratogenic effects of ribavirin on hamster and rat embryos","volume":"17","author":"Ferm","year":"1978","journal-title":"Teratology"},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-008X(80)90252-5","article-title":"Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice","volume":"52","author":"Kochhar","year":"1980","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib76","article-title":"Lethal mutagenesis of RNA viruses and approved drugs with antiviral mutagenic activity","volume":"14","author":"Hadj","year":"2022","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.micpath.2024.107051_bib77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/v15010244","article-title":"Antiviral susceptibilities of distinct lineages of influenza C and D viruses","volume":"15","author":"Takashita","year":"2023","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib79","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.micpath.2024.107051_bib80","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038687","article-title":"Influenza polymerase inhibitors: mechanisms of action and resistance","volume":"11","author":"Takashita","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.micpath.2024.107051_bib81","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib82","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01217-18","article-title":"Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing","volume":"93","author":"Goldhill","year":"2019","journal-title":"J. Virol."},{"issue":"45","key":"10.1016\/j.micpath.2024.107051_bib84","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/acsinfecdis.7b00120","article-title":"Broad spectrum inhibitor of influenza A and B viruses targeting the viral nucleoprotein","volume":"4","author":"White","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107051_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115678","article-title":"Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors","volume":"259","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.micpath.2024.107051_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28968","article-title":"Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses","volume":"95","author":"Li","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.micpath.2024.107051_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2021.106663","article-title":"Arbidol targeting influenza virus A Hemagglutinin; A comparative study","volume":"277","author":"Ahmed","year":"2021","journal-title":"Biophys. Chem."},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib89","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02141-21","article-title":"Glycomic analysis reveals that sialyltransferase inhibition is involved in the antiviral effects of arbidol","volume":"96","author":"Kang","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.micpath.2024.107051_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2022.107764","article-title":"Insights into binding molecular mechanism of hemagglutinin H3N2 of influenza virus complexed with arbidol and its derivative: a molecular dynamics simulation perspective","volume":"101","author":"Boonma","year":"2022","journal-title":"Comput. Biol. Chem."},{"issue":"8","key":"10.1016\/j.micpath.2024.107051_bib91","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acsinfecdis.2c00178","article-title":"Hemagglutinin stability determines influenza A virus susceptibility to a broad-spectrum fusion inhibitor arbidol","volume":"8","author":"Li","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107051_bib92","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"issue":"43","key":"10.1016\/j.micpath.2024.107051_bib93","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"6632","key":"10.1016\/j.micpath.2024.107051_bib94","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.add0875","article-title":"Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication","volume":"379","author":"Tsukamoto","year":"2023","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.micpath.2024.107051_bib95","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","article-title":"Antiviral peptides as promising therapeutic drugs","volume":"76","author":"Vilas Boas","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"19","key":"10.1016\/j.micpath.2024.107051_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911433","article-title":"Antiviral peptides as anti-influenza agents","volume":"23","author":"Agamennone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib97","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1021\/jm1002183","article-title":"Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy","volume":"53","author":"Matsubara","year":"2010","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib98","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41467-021-22964-w","article-title":"Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models","volume":"12","author":"Saito","year":"2021","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.micpath.2024.107051_bib99","doi-asserted-by":"crossref","first-page":"19446","DOI":"10.1074\/jbc.M110.216655","article-title":"High mannose-binding lectin with preference for the cluster of alpha1-2-mannose from the green alga Boodlea coacta is a potent entry inhibitor of HIV-1 and influenza viruses","volume":"286","author":"Sato","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2024.107051_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113523","article-title":"Traditional Chinese medicines as effective agents against influenza virus-induced pneumonia","volume":"153","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2024.107051_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.575803","article-title":"Traditional Chinese medicine in treating influenza: from basic science to clinical applications","volume":"11","author":"Xiong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.micpath.2024.107051_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.582322","article-title":"Role of traditional Chinese medicine in the management of viral pneumonia","volume":"11","author":"Xi","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib103","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12906-018-2216-7","article-title":"Sheng Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Compl. Alternative Med."},{"issue":"17","key":"10.1016\/j.micpath.2024.107051_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175724","article-title":"Urolithin M5 from the leaves of canarium album (lour.) DC. Inhibits influenza virus by targeting neuraminidase","volume":"27","author":"Xiao","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13020-023-00843-4","article-title":"A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin","volume":"18","author":"Luo","year":"2023","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ptr.6803","article-title":"Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase","volume":"35","author":"Wang","year":"2021","journal-title":"Phytother Res."},{"key":"10.1016\/j.micpath.2024.107051_bib107","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fphar.2019.00961","article-title":"Screening of antiviral components of ma huang tang and investigation on the ephedra alkaloids efficacy on influenza virus type A","volume":"10","author":"Wei","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.micpath.2024.107051_bib108","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2174\/1389557521666210927153001","article-title":"Pharmacological efficacy and safety of Glycyrrhiza glabra in the treatment of respiratory tract infections","volume":"22","author":"Wahab","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"issue":"1","key":"10.1016\/j.micpath.2024.107051_bib109","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12906-023-03858-4","article-title":"Determination of the synergistic anti-influenza effect of Huangqin Su tablet and Oseltamivir and investigation of mechanism of the tablet based on gut microbiota and network pharmacology","volume":"23","author":"Cui","year":"2023","journal-title":"BMC Complement Med. Ther."},{"key":"10.1016\/j.micpath.2024.107051_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3196375","article-title":"Lianhua-qingwen displays antiviral and anti-inflammatory activity and synergistic effects with oseltamivir against influenza B virus infection in the mouse model","volume":"2020","author":"Yang","year":"2020","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"2","key":"10.1016\/j.micpath.2024.107051_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2021.100027","article-title":"Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: a Chinese herbal medicine repurposed for COVID-19 pandemic","volume":"1","author":"Liang","year":"2021","journal-title":"Phytomed Plus"},{"key":"10.1016\/j.micpath.2024.107051_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111998","article-title":"The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule","volume":"142","author":"Shen","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2024.107051_bib113","article-title":"Screening of antiviral components of yinhuapinggan granule and protective effects of yinhuapinggan granule on MDCK cells with influenza A\/H1N1 virus","volume":"2022","author":"Chen","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.micpath.2024.107051_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116485","article-title":"Fu-Zheng-Xuan-Fei formula promotes macrophage polarization and Th17\/Treg cell homeostasis against the influenza B virus (Victoria strain) infection","volume":"312","author":"Xiao","year":"2023","journal-title":"J. Ethnopharmacol."},{"issue":"10","key":"10.1016\/j.micpath.2024.107051_bib115","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.micpath.2024.107051_bib116","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/jix606","article-title":"Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus","volume":"217","author":"Kiso","year":"2018","journal-title":"J. Infect. Dis."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024005187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024005187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T02:50:10Z","timestamp":1733971810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401024005187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":116,"alternative-id":["S0882401024005187"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107051","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influenza B virus: Target and acting mechanism of antiviral drugs","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107051"}}